Clinical affairs: Ongoing initiatives
EULAR Classification criteria for haemochromatosis arthropathy
Convenor: Patrick Kiely
Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis
Convenor: Paul Emery
Development And Validation of a EULAR disease activity score in adult onset Still’s Disease: the “DAVID” project
Convenor: Roberto Giacomelli
Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatology
Convenor: John Isaacs
EULAR Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases (including SLE and the antiphospholipid syndrome)
Convenor: Michael Nurmohamed/Maria Tektonidou
2019 Update of the EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies
Convenor: Josef Smolen/Laure Gossec
EULAR Recommendations /Points to Consider for the intra-articular treatment of arthropathies (including synoviorthesis)
Convenor: Jaqueline Uson
Update of the EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
EULAR recommendations for the management of difficult to treat rheumatoid arthritis
Update of the EULAR recommendations for the management of lupus nephritis
EULAR/ACR collaborative projects
For initiatives with international relevance, the relevant standing committee from EULAR seeks collaboration with the quality-of-care committee of the American College of Rheumatology (ACR). This cooperation includes the development and validation of criteria sets for the development of recommendations regarding conducting clinical trials.
EULAR and ACR strive for a transparent and collaborative relationship in order to avoid overlaps and to identify and promote synergies.
Call for task force members
To apply as task force member, please send your one-page letter of interest to participate and a short CV to Patrizia Jud (Patrizia.email@example.com).
Call is now closed.